Anteris Technologies Announces First Successful Implantation of DurAVR THV in a Valve-in-Valve Procedure - Seite 2

Chris Meduri, Anteris Technologies CMO, commented:

“This successful procedure further validates our extensive pre-clinical work in valve-in-valve as well as our extensive clinical experience in native aortic stenosis. This signals the viability of a purpose-built valve designed to achieve life-saving outcomes in a patient population currently treated with tradeoffs in mind. Eliminating that compromise would be widely beneficial to a rapidly growing population of patients whose current valve is failing.”

About Anteris Technologies (ASX: AVR)

Anteris Technologies (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, MN – a US MedTech hub, Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR THV, is a first-in-class biomimetic transcatheter aortic valve for the treatment of aortic stenosis (AS). The DurAVR THV, in concert with the ComASUR Delivery System, is designed to achieve pre-disease hemodynamic performance leading to improved clinical outcomes.

DurAVR THV has been designed in partnership with the world’s leading interventional cardiologists and is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This first-in-class biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

Anteris’ patented anti-calcification ADAPT tissue technology has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR Delivery System is designed to provide controlled deployment and accurate placement of the DurAVR THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve desired valve positioning.

Aortic stenosis is a common and serious valvular heart disease. It is the narrowing of the aortic valve, reducing blood flow from the heart as it opens. This means the heart must work harder to push the blood needed to function. Severe AS affects an estimated 3.4% of those aged ≥75 years in Europe and the USA.¹ In Australia, an estimated 150,000 people suffer from moderate to severe AS, with the figure projected to climb to 200,000 by 2031 due to the aging population.² The global TAVR market is estimated to be USD 10 billion by 2028.